We hypothesized that JP’s ability of improving inflammatory activity in SLE based on reducing IRAK1-NF-κB signaling in MRL/lpr mice and their bone marrow-derived macrophages (BMDMs). This evidence concerns the gene IRAK1 and systemic lupus erythematosus.